Try our beta test site
48 studies found for:    Biogen | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Biogen Multiple Sclerosis Pregnancy Exposure Registry
Conditions: Multiple Sclerosis;   Exposure During Pregnancy
Interventions: Drug: dimethyl fumarate;   Drug: Peginterferon beta-1a;   Drug: Dalclizumab High Yield Process
2 Recruiting An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
3 Not yet recruiting Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: BCD-054;   Biological: Avonex®
4 Available Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
Condition: Infantile-onset Spinal Muscular Atrophy (SMA)
Intervention: Drug: nusinersen
5 Recruiting Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BIIB076;   Drug: Placebo
6 Not yet recruiting MS PATHS Normative Sub-Study
Condition: Multiple Sclerosis (MS)
Intervention:
7 Recruiting Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Daclizumab
8 Recruiting Study to Evaluate BIIB059 in CLE With or Without SLE
Conditions: Systemic Lupus Erythematosus (SLE);   Active Cutaneous Lupus Erythematosus (CLE)
Interventions: Drug: BIIB059;   Drug: Placebo
9 Recruiting PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants
Condition: Trigeminal Neuralgia
Interventions: Drug: BIIB074;   Drug: Placebo
10 Recruiting Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Drug: natalizumab;   Drug: Placebo
11 Recruiting Single and Multiple Dose Study of BIIB067 (Isis-SOD1Rx) in Adults With Amyotrophic Lateral Sclerosis (ALS)
Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: BIIB067 (Isis-SOD1Rx);   Other: Placebo
12 Recruiting Methodology Study of Novel Outcome Measures to Assess Progression of ALS
Condition: Amyotrophic Lateral Sclerosis (ALS)
Intervention:
13 Recruiting Plegridy Satisfaction Study in Participants
Condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: peginterferon beta-1a
14 Recruiting Tecfidera and the Gut Microbiota
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: dimethyl fumarate;   Drug: injectable MS DMT
15 Recruiting Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
Conditions: Parkinson's Disease;   Healthy
Interventions: Drug: BIIB054;   Drug: Placebo
16 Recruiting Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
Condition: Multiple Sclerosis
Interventions: Drug: dimethyl fumarate;   Drug: montelukast;   Drug: Placebo
17 Recruiting Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: dimethyl fumarate;   Drug: Interferon β-1a
18 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: rFVIIIFc
19 Recruiting Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
Condition: Hemophilia B
Intervention: Biological: rFIXFc
20 Recruiting Plegridy Observational Program
Condition: Relapsing Forms of Multiple Sclerosis
Intervention: Drug: peginterferon beta-1a

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.